FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study-Reference-Cited by-同舟云学术

FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study

Published:2013-07 Issue:7 Volume:24 Page:1769-1777
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Brodowicz T.,Ciuleanu T.E.,Radosavljevic D.,Shacham-Shmueli E.,Vrbanec D.,Plate S.,Mrsic-Krmpotic Z.,Dank M.,Purkalne G.,Messinger D.,Zielinski C.C.

Funder

CECOG

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/7/1769/13789492/mdt116.pdf

Reference38 articles.

1. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer;Cunningham;N Engl J Med,2004

2. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system;Goldstein;Cancer,2001

3. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation;Sunada;Proc Natl Acad Sci USA,1986

4. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells;Fan;J Biol Chem,1994

5. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab;Li;Cancer Cell,2005

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Model‐informed Evidence for Clinical Non‐inferiority of Every‐2‐Weeks Versus Standard Weekly Dosing Schedule of Cetuximab in Metastatic Colorectal Cancer;Clinical Pharmacology & Therapeutics;2024-08-12

2. Longitudinal plasma proteome profiling reveals the diversity of biomarkers for diagnosis and cetuximab therapy response of colorectal cancer;Nature Communications;2024-02-01

3. Cetuximab every 2 weeks versus standard weekly dosing administration schedule;Future Oncology;2023-10-18

4. Optimizing the Dosing Regimen of Cetuximab and Ramucirumab Using the Model‐Informed Drug Development Paradigm;Clinical Pharmacology & Therapeutics;2023-05-11

5. Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201;Journal of Gastrointestinal Oncology;2023-04